Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population
Introduction: Breakthrough infections (BTI) threaten the progress of the COVID-19 vaccination program towards pandemic control. To better understand the future vaccine, knowing the BTI in the general population over a while is important. Aims and Objectives: The study aimed to compare the BTI among...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-06-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jfmpc.jfmpc_1714_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420784656711680 |
|---|---|
| author | Anuradha Nadda Neha Kapoor Sahil Sharma Nikita Sharma Viyusha T. Viswanathan Anamika Soni Ritu Attri Taranjot Kaur Nishu Gupta Nikhil Govil Kapil Goel Rahul Gupta |
| author_facet | Anuradha Nadda Neha Kapoor Sahil Sharma Nikita Sharma Viyusha T. Viswanathan Anamika Soni Ritu Attri Taranjot Kaur Nishu Gupta Nikhil Govil Kapil Goel Rahul Gupta |
| author_sort | Anuradha Nadda |
| collection | DOAJ |
| description | Introduction:
Breakthrough infections (BTI) threaten the progress of the COVID-19 vaccination program towards pandemic control. To better understand the future vaccine, knowing the BTI in the general population over a while is important.
Aims and Objectives:
The study aimed to compare the BTI among the general population after 1 year of completion of the primary series of Covishield and Covaxin.
Materials and Methods:
This hospital-based prospective study was conducted among the general population beneficiaries of a COVID-19 vaccination center. Clients aged 18 years or above who had completed second vaccine dose were enrolled using systematic random sampling and followed up for 1 year. Using a semi-structured questionnaire, participants were telephonically interviewed within 1 month, 6 months, and 12 months of the second vaccine dose.
Results:
Out of 1682 participants who completed the study, 958 (57.0%) and 724 (43.0%) participants received Covaxin and Covishield, respectively. Twenty-nine (3.0%) Covaxin recipients and 25 (3.5%) Covishield recipients reported BTI after 1 year of follow-up with no statistically significant difference among both groups (p-0.624). The binary logistic regression model showed that participants with either diabetes or hypertension had 1.22 times the risk of BTI compared to those without comorbidities (aOR: 1.219, CI: 0.072–20.716, p-0.891). BTI was not significantly associated with the type of vaccine, sex, employment status, and age category of the participants.
Conclusion:
The study suggests that regardless of the type of vaccine received, the population will be at the same risk and require similar future containment strategies. |
| format | Article |
| id | doaj-art-2bbe50fdba474ed89280b83fac07181f |
| institution | Kabale University |
| issn | 2249-4863 2278-7135 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Family Medicine and Primary Care |
| spelling | doaj-art-2bbe50fdba474ed89280b83fac07181f2025-08-20T03:31:38ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632278-71352025-06-011462307231210.4103/jfmpc.jfmpc_1714_24Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general populationAnuradha NaddaNeha KapoorSahil SharmaNikita SharmaViyusha T. ViswanathanAnamika SoniRitu AttriTaranjot KaurNishu GuptaNikhil GovilKapil GoelRahul GuptaIntroduction: Breakthrough infections (BTI) threaten the progress of the COVID-19 vaccination program towards pandemic control. To better understand the future vaccine, knowing the BTI in the general population over a while is important. Aims and Objectives: The study aimed to compare the BTI among the general population after 1 year of completion of the primary series of Covishield and Covaxin. Materials and Methods: This hospital-based prospective study was conducted among the general population beneficiaries of a COVID-19 vaccination center. Clients aged 18 years or above who had completed second vaccine dose were enrolled using systematic random sampling and followed up for 1 year. Using a semi-structured questionnaire, participants were telephonically interviewed within 1 month, 6 months, and 12 months of the second vaccine dose. Results: Out of 1682 participants who completed the study, 958 (57.0%) and 724 (43.0%) participants received Covaxin and Covishield, respectively. Twenty-nine (3.0%) Covaxin recipients and 25 (3.5%) Covishield recipients reported BTI after 1 year of follow-up with no statistically significant difference among both groups (p-0.624). The binary logistic regression model showed that participants with either diabetes or hypertension had 1.22 times the risk of BTI compared to those without comorbidities (aOR: 1.219, CI: 0.072–20.716, p-0.891). BTI was not significantly associated with the type of vaccine, sex, employment status, and age category of the participants. Conclusion: The study suggests that regardless of the type of vaccine received, the population will be at the same risk and require similar future containment strategies.https://journals.lww.com/10.4103/jfmpc.jfmpc_1714_24covid-19 vaccinesbreakthrough infectionsvaccinationbbv152 covid-19 vaccinechadox1 ncov-19pandemics |
| spellingShingle | Anuradha Nadda Neha Kapoor Sahil Sharma Nikita Sharma Viyusha T. Viswanathan Anamika Soni Ritu Attri Taranjot Kaur Nishu Gupta Nikhil Govil Kapil Goel Rahul Gupta Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population Journal of Family Medicine and Primary Care covid-19 vaccines breakthrough infections vaccination bbv152 covid-19 vaccine chadox1 ncov-19 pandemics |
| title | Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population |
| title_full | Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population |
| title_fullStr | Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population |
| title_full_unstemmed | Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population |
| title_short | Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population |
| title_sort | assessing breakthrough infections covishield late schedule versus covaxin a prospective comparative analysis in the general population |
| topic | covid-19 vaccines breakthrough infections vaccination bbv152 covid-19 vaccine chadox1 ncov-19 pandemics |
| url | https://journals.lww.com/10.4103/jfmpc.jfmpc_1714_24 |
| work_keys_str_mv | AT anuradhanadda assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT nehakapoor assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT sahilsharma assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT nikitasharma assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT viyushatviswanathan assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT anamikasoni assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT rituattri assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT taranjotkaur assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT nishugupta assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT nikhilgovil assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT kapilgoel assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation AT rahulgupta assessingbreakthroughinfectionscovishieldlatescheduleversuscovaxinaprospectivecomparativeanalysisinthegeneralpopulation |